(C) 2010 Elsevier Ireland Ltd. All rights
reserved.”
“Embryos with greater viability have a lower or ‘quieter’ amino acid metabolism than those which arrest. We have hypothesized this is due to non-viable embryos possessing greater cellular/molecular damage and consuming more nutrients, such as amino acids for repair processes. We have tested this proposition by measuring physical damage to DNA in bovine, porcine and human embryos at the blastocyst stage and relating the data to amino acid profiles during embryo development.\n\nAmino acid profiles of in vitro-derived porcine and bovine blastocysts were measured by high-performance liquid chromatography and the data related retrospectively to DNA damage in Selleckchem Panobinostat each individual blastomere using a modified alkaline comet assay. Amino acid profiles of spare human embryos on Day 2-3 were related to DNA damage at the blastocyst stage.\n\nA Fludarabine positive correlation between
amino acid turnover and DNA damage was apparent when each embryo was examined individually; a relationship exhibited by all three species. There was no relationship between DNA damage and embryo grade.\n\nAmino acid profiling of single embryos can provide a non-invasive marker of DNA damage at the blastocyst stage. The data are consistent with the quiet embryo hypothesis with viable embryos (lowest DNA damage) having the lowest amino acid turnover. Moreover, these data support the notion that metabolic profiling, in terms of amino acids, might be used to select single embryos for transfer in clinical IVF.”
“The synaptic vesicle is currently the most well-characterized cellular organelle. During neurotransmitter release it undergoes multiple cycles of exo- and endocytosis. Despite this the vesicle manages to retain its protein and lipid composition. How does this happen? Here we provide a brief overview of the molecular architecture of the synaptic
vesicle, and discuss recent studies investigating single vesicle behavior and the mechanisms controlling the vesicle’s molecular contents. (C) 2010 Elsevier Inc. All rights reserved.”
“Targeted biological therapy is becoming a standard in personalized medicine for patients with advanced stages of cancer. Treatment with cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, represents an example EGFR inhibitor of personalized anticancer the for patients with metastatic colorectal cancer and wild (non-mutated) type of the Kirsten rat sarcoma viral oncogene (KRAS). Here the role of cetuximab in treating metastatic colorectal cancer is discussed with a focus on the treatment of hepatic metastases.”
“Aqueous polymer dispersions are important raw materials used in a variety of industrial processes. They may contain particles with diameters ranging from 10 to 1500 nm. Polymer exposure alone may cause pulmonary lesions after inhalation exposure.